局灶冷冻消融治疗中危有利风险(GG2)前列腺癌的7年肿瘤学结局
中位随访7年期间,14.1%出现临床显著前列腺癌(csPCa)复发,3、5、7年无复发生存率分别为90.20%、78.36%、70.31%,无前列腺癌死亡,3例(0.01%)发生转移。非洲裔美国种族是csPCa复发的唯一显著独立预测因素。
要点
- FCA治疗严格筛选的单侧GG2中危有利风险前列腺癌,7年csPCa无复发生存率为70.31%。
- 非洲裔美国种族是术后csPCa复发的唯一显著独立预测因素。
- 7.5年时方案MRI依从性达90.9%,支持影像随访可行性。
核心结论
- FCA可作为符合MRI靶灶、无包膜外侵犯或远端尖部病变且对侧无GG≥2病变的单侧IFRPCa患者的治疗选择。
主要发现
- 无前列腺癌死亡,3例(0.01%)发生转移。
- 3、5、7年csPCa无复发生存率分别为90.20%、78.36%、70.31%。
- 发生csPCa复发者基线平均PSA显著更高。
- 非洲裔美国种族是csPCa复发的唯一显著独立预测因素。
关键数值与推荐
- 入组条件:单个MRI PIRADS 2-5靶灶与单侧IFRPCa一致,MRI无肉眼包膜外侵犯或极远端尖部病变,对侧无GG≥2病变。
- 监测方案:每6个月PSA,MRI于6-12个月、2、3.5、5.0、7.5年复查。
- 前列腺活检指征:PSA升高、MRI可疑或术者酌情。
临床怎么用
- 对严格筛选的单侧GG2中危有利风险前列腺癌,FCA可作为局灶治疗选项。
- 术后需按方案规律PSA与MRI随访,尤其关注非洲裔美国患者复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report 7-year oncological outcomes of focal cryo-ablation (FCA) for focal intermediate favorable-risk prostate cancer (IFRPCa). PATIENTS AND METHODS: Beginning March 2017, all men with focal IFRPCa undergoing FCA meeting the following eligibility criteria were enrolled in our longitudinal prospective study: a single MRI Prostate Imagine-Reporting and Data System (PIRADS) 2-5 target concordant with unilateral IFRPCa, no gross extraprostatic extension or very distal apical disease on MRI, and no Grade Group (GG) ≥2 contralateral to the MRI target. The oncological surveillance protocol included PSA testing every 6 months and MRI testing at 6-12 months, 2, 3.5, 5.0, and 7.5 years. Prostate biopsy was performed for rising PSA, suspicious MRI's or at the discretion of the surgeons. The main outcome measure was clinically significant prostate cancer (csPCa) recurrence. RESULTS: Two hundred seventy-six men were enrolled in the study. Overall, 39 (14.1%) developed a csPCa recurrence. Baseline mean PSA was significantly greater in subjects developing csPCa recurrence. There were no prostate cancer mortalities, and 3 (0.01%) developed metastasis. The csPCa recurrence-free survival at 3, 5, and 7 years was 90.20%, 78.36%, and 70.31%, respectively. African American race was the only significant independent predictor for developing a csPCa recurrence. Compliance with protocol MRI at 7.5 years was 90.9%. CONCLUSION: The present study supports FCA as a treatment option for focal IFRPCa associated with an MRI target with no evidence of extra-capsular extension or distal apical disease on MRI, and no contralateral GG >1 disease.
引用
- Lepor H, Fiske J, Tafa M, et al. Focal Cryo-ablation for Treatment of Intermediate Favorable Risk (Grade Group 2) Prostate Cancer. Urology. 2026. PMID: 42229815. doi:10.1016/j.urology.2026.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。